In vitro cytokine production and proliferation of T cells from patients with anti-proteinase 3- and antimyeloperoxidase-associated vasculitis, in response to proteinase 3 and myeloperoxidase

Arthritis and Rheumatism

Volumn 46, Issue 7, 2002, Pages 1894-1904

  Popa, E R ^a   Franssen, C F M ^a   Limburg, P C ^a   Huitema, M G ^a   Kallenberg, C G M ^a   Cohen Tervaert, J W ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CELL MARKER; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 6; KI 67 ANTIGEN; MYELOBLASTIN; MYELOPEROXIDASE; NEUTROPHIL CYTOPLASMIC ANTIBODY;

ADULT; AGED; ARTICLE; CELL PROLIFERATION; CELL STIMULATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; HUMAN; HUMAN CELL; IMMUNOREGULATION; IN VITRO STUDY; MALE; MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN FUNCTION; T LYMPHOCYTE ACTIVATION; TH1 CELL; TH2 CELL; VASCULITIS;

ADULT; AGED; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; AUTOANTIGENS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CD4-POSITIVE T-LYMPHOCYTES; CELL DIVISION; CYTOKINES; DNA-BINDING PROTEINS; FEMALE; HUMANS; INTERFERON TYPE II; INTERLEUKIN-10; INTERLEUKIN-2; INTERLEUKIN-6; MALE; MIDDLE AGED; MYELOBLASTIN; PEROXIDASE; SERINE ENDOPEPTIDASES; TRANSCRIPTION FACTORS; VASCULITIS, HYPERSENSITIVITY;

EID: 0036068953     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.10384     Document Type: Article

References (43)

1. Autoantibodies against neutrophils and monocytes: Tool for diagnosis and marker for disease activity in Wegener's granulomatosis
2. Autoantibodies against myeloid lysosomal enzymes in crescentic glomerulonephritis
3. Prospective study of radioimmunoassay for antibodies against neutrophil cytoplasm in diagnosis of systemic vasculitis
4. Association of autoantibodies to myeloperoxidase with different forms of vasculitis
5. Nomenclature of systemic vasculitides: Proposal of an international consensus conference
6. Prevention of relapses of Wegener's granulomatosis by treatment based on antineutrophil cytoplasmic antibody titre
7. Prediction of relapses in Wegener's granulomatosis by measurement of antineutrophil cytoplasmic antibody levels: A prospective study
8. Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro
9. Antibodies against granule proteins activate neutrophils in vitro
10. Autoantibodies developing to myeloperoxidase and proteinase 3 in systemic vasculitis stimulate neutrophil cytotoxicity towards cultured endothelial cells
11. Neutrophil activation in vitro and in vivo in Wegener's granulomatosis
12. Pathophysiology of ANCA-associated glomerulonephritis
13. Pulmonary vasculitis (Wegener's granulomatosis): Immunohistochemical study of T and B cell markers
14. Immunohistopathology of renal biopsies in Wegener's granulomatosis (WG): Clues to its pathogenesis?
15. Leukocyte analysis using monoclonal antibodies in human glomerulonephritis
16. Differential B- and T-cell activation in Wegener's granulomatosis
17. Activated CD4+ and CD8+ T-cell subsets in Wegener's granulomatosis
18. Elevated serum levels of soluble interleukin-2 receptor in patients with Wegener's granulomatosis: Association with disease activity
19. Serum markers of T cell activation in relapses of Wegener's granulomatosis
20. High plasma levels of the soluble form of CD30 activation molecule reflect disease activity in patients with Wegener's granulomatosis
21. Cyclosporin treatment of Wegener's granulomatosis (WG) and related diseases
22. Monoclonal -antibody therapy in systemic vasculitis
23. Longterm remission of intractable systemic vasculitis with monoclonal antibody therapy
24. T and B cell responses to neutrophil cytoplasmic antigens in systemic vasculitis
25. T-cell reactivity to proteinase 3 and myeloperoxidase in patients with Wegener's granulomatosis
26. Cell-mediated autoimmunity in patients with Wegener's granulomatosis
27. T cell responses to myeloperoxidase (MPO) and proteinase 3 (PR3) in patients with systemic vasculitis
28. T lymphocyte responses to anti-neutrophil cytoplasmic autoantibody (ANCA) antigens are present in patients with ANCA associated systemic vasculitis and persist during disease remission
29. Elevations of neutrophil proteinase 3 in serum of patients with Wegener's granulomatosis and polyarteritis nodosa
30. Proteinase 3, the major autoantigen of Wegener's granulomatosis, enhances IL-8 production by endothelial cells in vitro
31. Proteinase 3 enhances endothelial monocyte chemoattractant protein-1 production and induces increased adhesion of neutrophils to endothelial cells by upregulating intercellular cell adhesion molecule-1
32. The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis
33. Detection of auto-antibodies against myeloid lysosomal enzymes: A useful adjunct to classification of patients with biopsy-proven necrotizing arteritis
34. Interleukin-2
35. IL6 and the T-cell response
36. B-cell-stimulatory factor 2 (β2 interferon) functions as a second signal for interleukin 2 production by mature murine T cells
37. Enhancement of the interleukin 2 receptor expression on T cells by multiple B-lymphotrophic lymphokines
38. Interleukin-2 dependent and interleukin-2 independent pathways of regulation of thymocyte function by interleukin 6
39. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67
40. The cell cycle associated change of the Ki-67 reactive nuclear antigen expression
41. Active Wegener's granulomatosis is associated with HLA-DR+CD4+ T cells exhibiting an unbalanced Th1-type T cell cytokine pattern: Reversal with IL-10
42. Interleukin 10 and the interleukin-10 receptor
43. Differences between anti-myeloperoxidase- and anti-proteinase 3-associated renal disease